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Abstract 
 
 
Osteoprotegerin (OPG) is a secreted protein essential in bone turnover because of its role as a 
decoy receptor for the Receptor Activator of Nuclear Factor kB ligand (RANKL) in the 
osteoclasts, inhibiting their differentiation. However, there are additional ligands of OPG that 
confer multiple roles. Thus, OPG can promote cell survival, cell proliferation and facilitate 
migration through its binding to TNF-related apoptosis inducing ligand (TRAIL), 
glycosaminoglycans and proteoglycans. A large number of in vitro, in vivo and clinical 
studies provide evidences of the implication of OPG in vascular, bone, immune and tumor 
biology. This review aims to give an overview of the different ligands of OPG and their role 
in its biology.  
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Introduction 
The Tumor Necrosis Factor (TNF)/TNF receptor superfamily is composed by more than 40 
members, and controls a lot of genes essential for biological functions such as cellular 
differentiation, survival and death. Additionally TNF superfamily coordinates the 
development of numerous organs (Pfeffer 2003; Ware 2008). Among this family, 
Osteoprotegerin (OPG or TNFRSF11B according the international nomenclature) is soluble 
glycoprotein that exists as both a 60kDa monomer and a 120 kDa disulfide-linked dimer. 
OPG was originally characterized by two separate groups in 1997. Boyle and coworkers 
generated transgenic mice overexpressing various TNF receptor related cDNAs. A lineage of 
mice which over-expressed one specific cDNA developed a severe osteopetrosis due to a lack 
of osteoclasts. The protein encoded by this cDNA was therefore named osteoprotegerin, 
because it protected the bone from excessive resorption (Simonet et al. 1997). The second 
group in Japan reported a factor which was able to inhibit osteoclastogenesis (Yasuda et al. 
1998). However, it was not until 1998 that both proteins were found to be equivalent. 
Structurally, the mature form of OPG consists of 380 amino acids containing seven 
domains (Theoleyre et al. 2006; Baud'huin et al. 2007): four cysteine-rich N-terminal 
domains (domains 1-4), two death domain homologous regions (domains 5 and 6) and a C-
terminal heparin-binding domain (domain 7). Domains 1-4 are structurally related to the TNF 
receptor family and are sufficient to abolish osteoclast differentiation and domains 5 and 6 
can mediate a cytotoxic signal when they are included in a chimeric protein OPG-Fas 
(Yamaguchi et al. 1998) but their physiological functions remain unclear. The last domain 
possesses a heparin binding domain. Similar heparin binding domains has been observed in 
the structure of many other proteins such as fibroblast growth factors and their receptors in 
which it plays numerous key functions (activation, autophosphorylation, etc) (Eswarakumar et 
al. 2005; Guerrini et al. 2007). Additionally the presence of Cys-400 in the C-terminal 
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portionwithin domain 7 is essential for OPG dimerization with the formation of disulfide 
bound (Yamaguchi et al. 1998). 
As OPG belongs to the TNF receptor family, it suggests that OPG has almost one 
ligand. The historical partner of OPG is RANKL which was identified few months following 
the description of OPG by the two same groups (Lacey et al. 1998; Yasuda et al. 1998). 
RANKL was initially discovered by two groups working on TNF-related cytokines thanks by 
its ability to sustain dendritic cell survival (Anderson et al. 1997; Wong et al. 1997). OPG is 
therefore a decoy receptor for the pro-osteoclastic cytokine RANKL (Theoleyre et al. 2004; 
Baud'huin et al. 2007) with a high affinity equivalent to RANKL for its receptor RANK 
(TNFRSF11A) (Table 1). The binding of OPG to RANKL prevents the interaction of 
RANKL for RANK expressed on the cell surface of osteoclast precursors, and thus inhibits 
the formation of osteoclasts (Boyle et al. 2003). Since then, numerous ligands for OPG have 
been identified: TRAIL (Emery et al. 1998), syndecan-1 (Standal et al. 2002), 
glycosaminoglycans (GAGs) (Theoleyre et al. 2006; Lamoureux et al. 2009), von Willebrand 
Factor (Zannettino et al. 2005) and Factor VIII-von Willebrand Factor complex (Baud'huin et 
al. 2009) (Table 1). This review focuses on the multiple biological functions achieved by 
OPG through the binding to its various ligands. 
 
 5 
RANKL and TRAIL: ligands from the TNF family 
RANKL is a transmembrane glycoprotein expressed on the surface of osteoblasts, stromal 
cells and T cells, however this molecule can be cleaved by proteases to give soluble RANKL 
with the same biological activity. The proteolytic cleavage is carried out by matrix 
metalloproteases or ADAMs (Georges et al. 2009). In bone, RANKL binds to its specific 
receptor RANK which is expressed on the membrane of osteoclast progenitors. 
Stoichiometrically, RANKL forms an homotrimeric protein and interacts with three 
monomers of RANK linked by disulfide bounds (Theoleyre et al. 2006). The binding of 
RANK to RANKL leads to the activation of several pathways involved in the differentiation, 
activation and survival of osteoclast. The RANK/RANKL is thus mandatory for the formation 
of mature osteoclasts. It has been shown that mice lacking Rankl did not have osteoclasts and 
suffered from severe osteopetrosis (Kong et al. 1999). 
The osteoclastogenesis is a tightly regulated process with the modulation of 
RANK/RANKL signaling by OPG which acts as a decoy receptor for RANKL. In bone, OPG 
is secreted by stromal cells and other cell types including osteoblastic lineage cells. The 
evidence showing the importance of OPG in bone biology was provided by studies based on 
genetic experiments. OPG-overexpressing mice exhibit severe osteopetrosis and a reduced 
number of mature osteoclasts (Simonet et al. 1997) on the other hand OPG-knockout mice are 
osteoporotic with a decreased bone density and a high incidence of fractures and bone 
deformities (Bucay et al. 1998; Mizuno et al. 1998). The interaction between RANKL and 
OPG consists of two anchoring points on OPG for RANKL by amino acids 68, 69, 82, and 
amino acids 88±91, 111, and 116±120 (Figure 1) (Baud'huin et al. 2009). However, it has 
been shown that the homodimeric form of OPG exhibits a much greater higher affinity for the 
homotrimeric form of RANKL (Schneeweis et al. 2005; Theoleyre et al. 2006). More 
recently, the crystal structure of the interaction between RANKL and OPG was described 
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(Luan et al. 2012). In this study, the authors showed that OPG (Domains 1 to 4) is able to 
interact with RANKL in a 1:1 ratio, and blocks the accessibilities of important biding sites of 
RANKL to RANK. 
This competitive interaction within the triad RANK/RANKL/OPG suggests that OPG 
can have also an effect in tissues other than bone where RANKL is active. In this context, the 
RANKL-RANK system influences processes in the immune system. Both RANK-/- and 
RANKL-/- mice have a defect in the maturation of T and B cells suggesting by the phenotype 
of implicating these molecules in lymphocyte and lymph node development (Dougall et al. 
1999; Kong et al. 1999). From this perspective, Yun and coworkers showed that OPG 
regulates B cell maturation and development; population of B cells was indeed increased in 
OPG-null mice. Moreover, the dendritic cells generated from these mice have an increased 
ability to stimulate T cells (Yun et al. 2001). This study suggests that OPG has a pivotal role 
in the immune response and can mediate cell survival. 
This latter function is reinforced by the fact that OPG is able to bind to TNF-related 
apoptosis inducing ligand (TRAIL) and thus block TRAIL-induced apoptosis of Jurkat cells 
(Emery et al. 1998). TRAIL is a member of the TNF superfamily produced by immune cells 
within the tumor environment. TRAIL binds to its receptors as a homotrimer form, this 
trimeric form being biologically much more active than the monomeric one (Wiley et al. 
1995). There are five TRAIL receptors described so far; two of these receptors (DR4 and 
DR5) contain death domain motifs and promote apoptosis. On the other hand, DcR1, DcR2 
and OPG are unable to induce apoptosis and function as decoy receptors. OPG is binding to 
TRAIL with a comparable affinity to that of RANKL (Table 1) and the binding sites involve 
on OPG residues (Figure 1). The direct biological consequence of the interaction of OPG with 
TRAIL is the inhibition of TRAIL-induced apoptosis in numerous cancer cells (Holen et al. 
2002; Shipman et al. 2003; Neville-Webbe et al. 2004). This mechanism could be important 
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in the release from cell death, as suggested by the production of OPG by tumor cells (Holen et 
al. 2002; Heymann 2012). 
Additional studies have been performed using bone marrow stromal cells (BMSCs) 
derived from either breast or prostate cancer patients. In both cancer types, BMSCs were 
found to produce sufficient levels of OPG to protect tumor cells from TRAIL-induced 
apoptosis. This suggests that bone-derived OPG may be involved in promoting survival of 
these tumor cell types within the bone microenvironment (Neville-Webbe et al. 2004; 
Nyambo et al. 2004). In this context, a peptide-mimetic of OPG (OP3-4) was developed to 
treat bone disease in multiple myeloma and keep the TRAIL activity. OP3-4 was able to 
inhibit osteoclastogenesis of murine blood mononuclear cells but did not inhibit TRAIL-
induced apoptosis of multiple myeloma cells (Heath et al. 2007). Moreover, recent in vivo 
experiment showed that anticancer efficacy of recombinant soluble Apo2L/TRAIL is retained 
in the bone microenvironment where biologically active OPG may be present at high 
concentrations (Zinonos et al. 2011). Taken together, OPG may have a dual function in 
tumor, promoting cancer cell survival through its binding to TRAIL and on the other hand 
limiting the tumor growth in cancer induced bone disease due to the inhibition of RANKL. 
Thus, in a model of osteosarcoma, OPG administered by gene transfer reduced tumor 
incidence and local tumor growth (Lamoureux et al. 2007). The mechanism suggested 
mentioned that OPG exerts indirect inhibitory effect on tumor progression through the 
inhibition of RANKL whose production is enhanced in bone tumor environment. 
The ability of OPG to bind both to RANKL and TRAIL gives to him the potency to 
regulate bone biology and tumor biology through direct effect on osteoclasts or cancer cells. 
However, in vascular biology, these three partners play a pivotal role which has numerous 
outcomes in the physiopathology of vascular system. OPG is largely expressed in the vascular 
tissues including the heart, arteries and veins, and is constitutively secreted by endothelial 
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cells and vascular smooth muscle cells (Chikatsu et al. 2002; Collin-Osdoby 2004; Chollet et 
al. 2010). In oncologic context, endothelial cells closely located to tumor cells strongly 
express OPG, especially in metastatic foci (Heymann et al. 2008). The presence of arterial 
calcification of the media of the aorta and the renal arteries in OPG-deficient mice suggest the 
involvement of OPG in vascular biology (Bucay et al. 1998). In accordance with these data, 
Price and co-workers showed that administration of exogenous OPG prevent vascular 
calcification induced by warfarin or high vitamin D doses (Price et al. 2001). Paradoxically, 
clinical studies suggest that high serum OPG levels correlate with the severity of vascular 
calcification, coronary artery disease and heart failure. (Ueland et al. 2005; Ziegler et al. 
2005; Helske et al. 2007). Very recently, it has been shown that OPG is more frequently 
expressed in atheromatous carotid plaques than femoral specimens, and correlates with the 
abundance of macrophages in the lesions (Heymann et al. 2012). These clinical findings are 
controversial with in vitro data. Indeed the inhibitory effect of OPG on vascular calcification 
in animal models could be passive or cellular. As mentioned above, OPG exerts an anti-
apoptotic effect towards TRAIL and decreases in consequence the number of apoptotic bodies 
that may serve as nucleation sites for passive mineralization (Fleishman et al. 1990; 
Benslimane-Ahmim et al. 2011). Several studies have shown also that recombinant OPG can 
promote the survival/proliferation of mature vascular endothelial cells (Malyankar et al. 2000; 
Pritzker et al. 2004; Cross et al. 2006; Kobayashi-Sakamoto et al. 2006; McGonigle et al. 
2009). Similarly, Lawrie et al showed OPG promotes the proliferation and the migration of 
pulmonary artery smooth muscle cell, and thus evidenced an important role of OPG in the 
pathogenesis of pulmonary arterial hypertension (Lawrie et al. 2008). However, the precise 
mechanism remains unclear and seems to involve multipartners. One study although suggests 
that OPG is blocking the apoptosis induced by TRAIL (Pritzker et al. 2004). It has been 
clearly demonstrated that OPG is able to stimulate endothelial colony-forming cells and thus 
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leads to the formation of new blood vessels in vivo (Benslimane-Ahmim et al. 2011). These 
findings confirmed the work of McGonigle and collaborators who described that OPG 
increases angiogenesis (McGonigle et al. 2009) but interestingly they suggest that OPG exerts 
its effect through the inhibition of the binding RANK/RANKL. This capacity of OPG to 
induce new blood vessels formation gives to OPG a potential proangiogenic role in tumors as 
suggested by different studies (Cross et al. 2006; Secchiero et al. 2008). More recently, 
Benslimane-Ahmin et al. (in press) revealed using proteomic approaches that the 
proangiogenic properties of OPG appeared to be mediated by the proteoglycan syndecan-1, 
although OPG 1-194 lacking its heparin-binding domain still had pro-vasculogenic effects in 
vitro and in vivo. All these effects were significantly attenuated by endothelial colony-forming 
cells incubation with the CXCR4 antagonist AMD-3100, and by prior heparan sulphate 
proteoglycan disruption. Taken together, these data suggest a central role of OPG in vascular 
biology. The mechanism of action remains unclear and seems to involve RANKL and TRAIL 
but the interplay between these molecules is not sufficient to explain the different functions of 
OPG in vasculature.  
 
Glycoaminoglycans and proteoglycans : ligands from the extracellular matrix. 
Glycoaminoglycans (GAGs) are linear polymers of repeated disaccharidic units, bearing 
sulfate residues. The number and the position of sulfation are extremely variable, depending 
on the tissue, cell and metabolic context, ensuring structural variability in these 
polysaccharides (Bernfield et al. 1999). GAGs have an extended diversity of functions and are 
implicated in various biological processes such as morphogenesis, tissue structuring and 
organization, blood clotting. All GAGs, apart from hyaluronic acid (cartilage, vitreous humor) 
and heparin (mast cells), are present in the body as proteoglycans (PGs), covalently attached 
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to a core protein. PGs are present in many tissues, in the extracellular matrix or associated to 
the cell membrane. 
The full length OPG binds to a wide variety of GAGs through its heparin binding 
domain in contrast to OPG-Fc in which the heparin-binding domain is lacking (Theoleyre et 
al. 2006; Lamoureux et al. 2009). The capacity of GAGs to bind to OPG can be evaluated by 
BIAcore analysis (Figure 2). Among the different GAGs, heparin presents the highest affinity 
for OPG (Kd: 1.3.10-10M for heparin, see Table 1).The dissociation constant is higher 
(hundred fold) for dermatan sulfate (DS) and chondroitin sulfate (CS) (3.7.10-8 and 2.10-8 M 
respectively, Table1). This lower affinity is mainly due to the degree of sulfation as recently 
confirmed by Robinson et al. and by Salbach et al. (Robinson et al. 2012; Salbach et al. 
2012). Heparin, indeed, is the most sulfated GAGs compared to CS and DS (Velasco et al. 
2010). Moreover, a highly sulfated exopoly-saccharide derived from Altermonasinfernus 
(Velasco et al. 2011) has a binding affinity comparable to heparin (2.10-10 M, Table 1). The 
length of GAGs is another property of GAGs that govern their binding to OPG. As shown in 
Figure 2 and Table 1, oligosaccharide made of 4 sugar units (dp4) is much less affine for OPG 
than an oligosaccharide made of 18 sugar units (dp18) (Kd of 7.10-7 and 2.8.10-8 M 
respectively). As represented in Figure 2F, heparin is able to shift the binding of OPG to 
heparin immobilized on the sensorchip. The other GAGs studied are also able to shift the 
binding but a concentration 100 fold greater is required. This competition binding confirmed 
the importance of sulfation and size of GAGs for their biological activities. Thus, we have 
recently showed that GAGs act directly on osteoclastogenesis (Baud'huin et al. 2011). We 
found that heparin and others GAGs are able to inhibit the differentiation of osteoclast 
precursors into osteoclasts through an inhibition of cell adhesion. Our study confirmed also 
that the length and the sulfation are critical parameters in the inhibition of osteoclastogenesis. 
On the contrary, Irie and co-workers (Irie et al. 2007) showed that GAGs by binding to OPG 
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prevent OPG-mediated inhibition of osteoclastic differentiation, and therefore enhance bone 
resorption. Furthermore, Lamoureux et al. showed that GAGs inhibit full length OPG binding 
to TRAIL or to RANKL but not OPG truncated form lacking its heparin binding domain 
(Lamoureux et al. 2009). Thus, GAGs may represent potent regulators of OPG availability 
and anti-tumor activity in bone tumor microenvironment (Lamoureux et al. 2008). 
The binding of OPG with GAGs implies also activities through interaction with PGs. 
The first role of the OPG heparin-binding domain has been revealed by Standal (Standal et al. 
2002) who demonstrated that myeloma cells internalize and degrade OPG through its binding 
to syndecan-1 and consequently increase the local RANKL concentration andso induce 
osteolysis in patients. Moreover, OPG induces osteopontin expression via syndecan-1 and 
activates phosphoinositol 3-kinase/Akt in human periodontal ligament cells (Yongchaitrakul 
et al. 2009). PGs are also involved in OPG-induced chemotaxis of monocytes (Mosheimer et 
al. 2005). Indeed, OPG can interact with syndecan-1 expressed by monocytes (potential 
osteoclast precursors) and can stimulate the cell migration. In this context, OPG is a 
chemotactic factor for monocytes which can be recruited in inflammatory context or during 
osteolysis process.OPG seems also to modulate cell adhesion. Indeed, OPG stimulates the 
expression of the cell adhesion molecule angiopoietin-2 in TNF-ĮDFWLYDWHGFHOOV(Mangan et 
al. 2007), increases leucocyte adhesion to endothelial cells (Zauli et al. 2007) and stimulates 
proliferation and migration of human microvascular endothelial cells (Kobayashi-Sakamoto et 
al. 2008). Proteoglycans and GAGs have been suspected to initiate these OPG activities. 
Taken together, these data show that PGs and GAGs are key partners for biological 
activities of OPG (inhibition of osteoclastogenesis in vitro, bioavailability of OPG and 
monocyte chemotaxis in favour of pro-osteolytic activity). In this context, we investigate the 
role of OPG on human monocytes adhesion and its control by GAGs. After 5 days of culture, 
human CD14+ cells cultured in the presence of human OPG (100 ng/mL) strongly adhere to 
 12 
the plastic, whereas very few cells adhere in culture medium alone (0.3% of the initial 
monocytes number) (Figure3A). This is confirmed by the cell counting, OPG increased by 25 
fold the number of adherent monocytes (Figure 3B). When 125 µg/mL of heparin was added 
to the OPG-containing culture medium, the effect of OPG on CD14+ cell adhesion was 
completely abolished (Figure 3A, p < 0.001). The sulfation and the size of the GAGs chains 
are involved in this inhibition of OPG-mediated adhesion. Thud, DS and dp18 added to the 
culture are able to inhibit OPG effect with the same intensity as heparin (99% of inhibition, 
Figure 3C). On the contrary, the OPG-induced CD14+ cell adhesion was inhibited by 50%in 
the presence of dp4 and chondroitin sulfate (Figure 3C).We then investigated the signaling 
pathway involved in the adhesion of CD14+ cells induced by OPG. We found that OPG is 
able to activate the PI3k / Akt pathway. As shown in Figure 2D, OPG induces 
phosphorylation of Akt after 10 minutes which is maintained at 45 minutes. The induction of 
phosphorylation was inhibited by heparin. Our data suggest that OPG could promote 
monocyte adhesion through an Akt/PI3-Kinase signaling pathway and recruit monocytes 
where OPG is produced (bone, endothelial cells). However, this phenomenon is a long 
process during around 5 days, compare to the ability of OPG to induce leucocyte adhesion to 
endothelial cells in 5 to 15 minutes (Zauli et al. 2007). This data suggests that OPG facilitates 
the recruitment of monocytes where OPG is produced, such as bone microenvironment, 
vasculature and tumor context. 
 
von Willebrand factor/factor VIII complex : ligand from the vascular compartment 
Factor VIII (FVIII) associated with the von Willebrand factor (vWF) is a key protagonist of 
the coagulation process as evidenced in patients suffering from hemophilia A (Bolton-Maggs 
et al. 2003). vWF enables the recruitment of platelets while factor VIII acts as a catalysor of 
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the blood clotting. In the circulation, FVIII is non-covalently complexed with vWF to form 
the FVIII/vWF complex. 
In 2005, Zannettino and co-workers demonstrated that vWF is associated with OPG in 
Weibel Palade bodies of endothelial cells (Zannettino et al. 2005). More recently, it has been 
shown that OPG is also colocalised with vWF in alpha granules of platelets and 
megakaryocytes (Chollet et al. 2010). OPG interacts with the A1 domain of vWF and remains 
associated after secretion from endothelial cells (Shahbazi et al. 2007). The binding site of 
OPG to vWF has common domain with the binding site of GP1Ba protein to vWF which 
facilitates initial platelet adhesion (Figure 4). The binding affinity of vWF for OPG (3,5.10-9 
M) is comparable with that of OPG for RANKL as mentioned in Table 1. Taken together, 
these data support a possible role of vWF-OPG complex in regulation of endothelial cells 
survival, osteoclast differentiation, vascular injury and inflammation such as thrombus 
formation (Zannettino et al. 2005; Lenting et al. 2010). 
The complex FVIII/vWF is also able to bind to OPG (Kd = 7,2.10-8 M, Table 1), 
blocking the interaction of OPG with TRAIL suggesting a potential function ofFVIII/vWF 
complex in cancer development (Baud'huin et al. 2009). Moreover, the binding of OPG to 
FVIII/vWF complex reinforces the OPG-inhibition of RANKL-induced osteoclastogenesis 
making a direct link between vascular and bone biology (Baud'huin et al. 2009). Recently, 
Melchiorre et al. showed that the synovium in hemophilic arthropathy highly expressed 
RANK and RANKL in contrast to OPG which decreased suggesting an activation of the 
resorptive process. They concluded that low tissue expression of OPG paralleled its serum 
levels and the severity of hemophilic arthropathy (Melchiorre et al., 2012). .These data are 
consistent with a randomized study showing that the prophylaxis with recombinant Factor 
VIII prevents joint damages in young haemophilic patients (Manco-Johnson et al. 2007), 
possibly through a decrease in osteoclastogenesis.  
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Conclusions 
OPG has mainly been described as an anti-resorptive cytokine, as the first ligand reported was 
RANKL. However since that time, numerous ligands were described and studied in the last 
fifteen years giving to OPG an important role in vascular, tumor and immune biology (Figure 
5). Clinical outcomes confirm that OPG is an active cytokine in a wide range of pathologies 
(osteoporosis, arthritis, vascular calcification, cancer bone-related disease) and can be 
considered as a biological marker or/and therapeutic targets for these pathologies. But the 
mechanisms by which OPG and its multiple partners act together and/or sequentially remain 
uncertain and need further investigation.  
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Figure legends 
 
Figure 1: Structure of OPG in interaction with RANKL or TRAIL. OPG (red, model as 
described previously (Baud'huin et al. 2009)), was superposed on RANK (PDB id:3ME2, 
(Liu et al. 2010)) or DR5 (PDB id: 1D0G, (Hymowitz et al. 1999)) to conserve the receptor 
orientation observed in the crystallographic structures and the position of their respective 
ligands RANKL (green) or TRAIL (blue). Monomers only are presented for clarity. All 
proteins are represented with a transparent van der Walls surface and their secondary structure 
formed by an anti-parallel beta-sheets scaffold for RANKL and TRAIL or successive anti-
parallel beta sheets regrouped in cystein-rich domains (CRD) for OPG are displayed in 
ribbon. The superposition was made using Discovery Studio 3.1 (Accelrys Inc., San Diego, 
USA) and the final rendering using POV-Ray (http://www.povray.org) and The GIMP 
(http://www.gimp.org). 
 
Figure 2: GAGs bind to OPG with various affinities. Full-length human OPG (1 µg/mL in 5 
mM maleate, pH 6.0) was covalently immobilized to dextran matrix of a CM5 sensor chip 
(BIAcore) at a flow rate of 5 ȝOPLQ. Immobilisation level of 4000 RU was then obtained. 
Binding assays were performed at 25°C in 10 mMHepes buffer, pH 7.4, containing 0.15 M 
NaCl and 0.005% P20 surfactant (HBS-P buffer, BIAcore). Increasing concentrations of (A) 
heparin (rage from 0.5 nM to 20 nM), (B) dermatan sulphate, (C) chondroitin sulphate (range 
from 100 nM to 3200 nM), (D) dp 4 (range from 1.6 µM to 12.8 µM) or (E) dp 18 (range 
from 100 nM to 3200 nM) were injected over the immobilized OPG at a flow rate of 60 
ȝl/min, with 1 min association and 8 min dissociation. Kds of OPG for GAGs were determined 
using single cycle kinetics by ½ dilutions. The resulting sensorgrams were fitted using BiaEval 
4.1 sRIWZDUH %,$FRUH$OO H[SHULPHQWVZHUHSHUIRUPHGDWÛ&. (F ) Biotinylated heparin 
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was immobilized on a SA chip, and OPG was incubated for 2 hours with different GAGs at 
several concentrations. The couple OPG-GAGs was then injected on the immobilized heparin 
and the fixation of OPG to heparin was measured. 
 
Figure 3: OPG induced adhesion of human CD14+cells which is reversed by GAGs.106 
cells were seeded in 6-wells plate, and cultured for 3 days in the presence or the absence of 
full length- OPG (100 ng/mL) and/or heparin (125 µg/mL) (A,B) or different 
glycosaminoglycans (C) (5 µM). After 3 days, cells were washedwith PBS, and observed 
under light microscope (Leica DM IRB, Camera: Olympus D70, Analysis software: Olympus 
DP controller/Manager) (original magnification x100) (A), then detached by trypsin-EDTA 
dissociation and counted (B) RUDIWHUZDVKLQJ/RIĮ-MEM supplemented with 10% FCS 
was added as well as 50µL of XTT and OD was read at 490nm after 4h incubation at 
37°C(C). Experiments were performed three times in triplicate. ### P<0.001 compared to the 
control; *** P<0.001 compared to OPG.CD14+ cells were stimulated for 10 or 45 min with 
100 ng/mL OPG, in presence or not of 125 µg/mL heparin and (D) western blot analysis was 
performed on cell lysates to determine the level of Akt phosphorylation. Actin informed about 
equal loading charge Experiments were performed three times, and a representative blot is 
shown. 
 
Figure 4: Binding modes comparison of various vWF partners. Top left: amino acids 
involved in OPG recognition (green). Top middle: amino acids involved in heparin 
recognition (Adachi et al. 2006). Top right: amino acids involved in GPIba recognition 
(orange, PDB id: 1SQ0, (Dumas et al. 2004)). On the opposite face of the A1 domain, 
bitiscetin (cyan, PDB id: 1UEX, (Maita et al. 2003)) and botrocetin (purple, PDB id: 1IJK, 
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(Fukuda et al. 2002)) binding domains. N-terminal (brown) and C-terminal (blue) ends of the 
A1 vWFdomain are in tube representation. 
 
Figure 5: Schematic representation of the involvement of OPG in vascular, bone and 
cancer biology. OPG is biological active on several tissues mainly as a decoy receptor for 
ligands thus blocking their activity. As a result, OPG is inhibiting activities of RANKL and 
TRAIL in bone, vascular, tumor and immune biology. However, OPG can acts directly on 
cells by interacting with syndecans and promoting adhesion or migration 
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